Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives $11.13 Consensus Target Price from Analysts

Cardiff Oncology, Inc. (NASDAQ:CRDF) has received a consensus recommendation of “Moderate Buy” from the six research firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $11.1250.

A number of brokerages recently weighed in on CRDF. Weiss Ratings restated a “sell (d-)” rating on shares of Cardiff Oncology in a report on Wednesday, October 8th. Noble Financial started coverage on Cardiff Oncology in a report on Monday, January 5th. They issued an “outperform” rating and a $12.00 target price for the company.

Cardiff Oncology Stock Performance

Shares of CRDF stock opened at $2.88 on Friday. Cardiff Oncology has a one year low of $1.90 and a one year high of $4.99. The company’s 50-day moving average is $2.52 and its 200 day moving average is $2.57. The company has a market capitalization of $194.00 million, a price-to-earnings ratio of -3.65 and a beta of 1.40.

Cardiff Oncology (NASDAQ:CRDF) last issued its earnings results on Thursday, November 6th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.03. Cardiff Oncology had a negative net margin of 10,064.27% and a negative return on equity of 77.21%. The business had revenue of $0.12 million during the quarter, compared to analysts’ expectations of $0.12 million. As a group, research analysts predict that Cardiff Oncology will post -0.99 earnings per share for the current fiscal year.

Institutional Trading of Cardiff Oncology

A number of institutional investors have recently made changes to their positions in the stock. Flputnam Investment Management Co. boosted its holdings in Cardiff Oncology by 1,008.8% in the third quarter. Flputnam Investment Management Co. now owns 597,233 shares of the company’s stock worth $1,230,000 after purchasing an additional 543,370 shares during the last quarter. Blair William & Co. IL raised its stake in Cardiff Oncology by 44.1% during the 2nd quarter. Blair William & Co. IL now owns 2,524,118 shares of the company’s stock valued at $7,951,000 after buying an additional 772,844 shares during the last quarter. Belpointe Asset Management LLC bought a new position in shares of Cardiff Oncology during the 1st quarter valued at $37,000. AlphaCore Capital LLC purchased a new position in shares of Cardiff Oncology in the 2nd quarter worth $320,000. Finally, SteelPeak Wealth LLC grew its holdings in shares of Cardiff Oncology by 23.2% in the second quarter. SteelPeak Wealth LLC now owns 22,800 shares of the company’s stock worth $72,000 after acquiring an additional 4,300 shares during the period. Hedge funds and other institutional investors own 16.29% of the company’s stock.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.